Skip to main content

Market Overview

Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts

Share:
Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts
  • Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub.
  • Catalent has acquired Promethera’s Hepatic Cell Therapy Support SA (HCTS) subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. The financial terms of the deal were not disclosed.
  • The pickup will help Catalent move into plasmid DNA production, complementing its recent purchase of Delphi Genetics, located at Catalent’s growing campus in Gosselies. That buyout added a 17,000-square-foot facility.
  • The HCTS site comes equipped with existing cleanroom infrastructure, process development, quality control laboratories, and warehouse space and will be equipped to provide pDNA manufacturing up to a 500-liter scale, Catalent said.
  • Catalent expects to start outfitting the facility immediately and plans to add more than 200 jobs at the facility, the company said.
  • Price Action: CTLT shares are down 1.35% at $105.04 during market trading hours on the last check Thursday.
 

Related Articles (CTLT)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech M&A News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com